BTA Holders, Further comments from this post on Recombinomics are relevant to the coming flu season in Australia.
It emphasises the importance of Biota's "Relenza" anti-viral as the only alternative anti-viral to Tamiflu.
Tamiflu resistance due to the H274Y mutation was one of the major reasons why the US Government awarded Biota US$235m to progress trials and manufacturing capacity for "Lani" long-acting influenza antiviral.
H1N1pdm09 is the pandemic "swine flu" strain that spread around the world 2 years ago.
"The CDC description in week 19 FluView support clonal expansion since 13/16 cases had no Tamiflu exposure. Moreover, at least one of the three with Tamiflu exposure had reportable H274Y after 1 day of treatment, indicating H274Y was present prior to treatment. H274Y in two family members further support transmission of Tamiflu resistant H1N1pdm09, and at least two of the cases outside of Texas also had no exposure to Tamiflu.
The extended timeframe (January through April) and the wide geographical reach (Mexico City to Texas followed by spread to California and Illinois) indicate H274Y is far more widespread than the 22 confirmed cases in the United States and Mexico. Moreover, the spread is in a subclade that is dominant in Mexco and Texas, but has also spread throughout the United States.
Although the current flu season in the United States and Mexico is ending, the spread of this sub-clade to the southern hemisphere is likely, raising concerns that the spread to H274Y in H1N1pdm09 will mimic the fixing of H274Y in seasonal H1N1 in the 2008/2009 flu season."
BTA Price at posting:
83.5¢ Sentiment: Hold Disclosure: Held